0000899243-16-015840.txt : 20160311
0000899243-16-015840.hdr.sgml : 20160311
20160311204018
ACCESSION NUMBER: 0000899243-16-015840
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160301
FILED AS OF DATE: 20160311
DATE AS OF CHANGE: 20160311
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: El-Hibri Fuad
CENTRAL INDEX KEY: 0001380185
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 161502262
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2016-03-01
2016-03-03
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380185
El-Hibri Fuad
400 PROFESSIONAL DRIVE,
SUITE 400
GAITHERSBURG
MD
20879
1
1
1
0
Chairman
Common Stock
1771605
D
Common Stock
2350331
I
By Intervac, L.L.C.
Common Stock
1524155
I
By Biovac, L.L.C.
Restrictive Stock Units
2016-03-01
4
A
0
26303
0.00
A
Common Stock
26303
106982
D
This form 4 is being amended to reflect a change in reporting convention by backing out from Table I Mr. El-Hibri's unvested restricted stock units. Such unvested restricted stock units are instead reported on Table II. The 1,771,605 shares of securities beneficially owned directly by Mr. El-Hibri does not include unvested restricted stock units.
Mr. El-Hibri's holdings through Intervac, L.L.C. include 1,638,403 shares of Common Stock held by Mr. El-Hibri and his wife, as tenants by the entirety, through their 37.7% equity interest in Intervac, L.L.C.; 127,721 shares held by Mr. El-Hibri's wife; and 584,207 shares held by trusts indirectly controlled by Mr. El-Hibri or his wife. Mr. El-Hibri disclaims beneficial ownership, for purposes of Section 16 of the Exchange Act or otherwise, of those shares held solely by his wife and those shares held by the trusts.
Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.
This number corrects a historical scrivener's error that occurred more than two years ago. Prior to the transaction reported herein, for purposes of Section 16 of the Exchange Act, Mr. El-Hibri directly held a pecuniary interest in 1,771,605 shares of Common Stock.
This form 4 is being amended to reflect a change in reporting convention. The restrictive stock units set forth in Table II reflect Mr. El Hibri's unvested RSUs that were backed out of Table I.
Each restricted stock unit represents the right of Mr. El-Hibri to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
The restricted stock units and options vest in three equal installments on February 28, 2017, February 28, 2018 and February 28, 2019.
/s/ Carl A. Valenstein, attorney-in-fact
2016-03-11